Twist Bioscience stake reported at 4.21% by EdgePoint

Rhea-AI Filing Summary

EdgePoint Investment Group Inc. filed an amended Schedule 13G reporting its beneficial ownership of common stock of Twist Bioscience Corp. EdgePoint reports beneficial ownership of 2,521,635 shares, representing 4.21% of the outstanding common stock as of June 30, 2026.

EdgePoint reports 1,945,483 shares with sole voting and dispositive power and 576,152 shares with shared voting and dispositive power. The filing notes that EdgePoint acts as investment manager for multiple private investment funds and mutual fund trusts that directly own the shares and that its holdings represent ownership of 5 percent or less of the class.

Key Figures

Beneficial ownership: 2,521,635 shares Ownership percentage: 4.21% Sole voting power: 1,945,483 shares +3 more

6 metrics

Beneficial ownership 2,521,635 shares Common stock beneficially owned by EdgePoint as of June 30, 2026

Ownership percentage 4.21% Percent of Twist Bioscience common stock class held by EdgePoint

Sole voting power 1,945,483 shares Shares over which EdgePoint has sole power to vote or direct the vote

Shared voting power 576,152 shares Shares over which EdgePoint has shared power to vote or direct the vote

Sole dispositive power 1,945,483 shares Shares over which EdgePoint has sole power to dispose or direct disposition

Shared dispositive power 576,152 shares Shares over which EdgePoint has shared power to dispose or direct disposition

Key Terms

beneficially owned, sole voting power, shared dispositive power, investment manager, +1 more

5 terms

beneficially owned financial

"Amount beneficially owned: 2,521,635"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole voting power financial

"Sole power to vote or to direct the vote: 1,945,483"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

shared dispositive power financial

"Shared power to dispose or to direct the disposition of: 576,152"

investment manager financial

"EdgePoint acts as investment manager to, and exercises investment discretion"

mutual fund trusts financial

"directly owned by, a number of private investment funds and mutual fund trusts"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What percentage of Twist Bioscience (TWST) does EdgePoint Investment Group own?

EdgePoint Investment Group reports beneficial ownership of 4.21% of Twist Bioscience’s common stock. This corresponds to 2,521,635 shares as of June 30, 2026, held across funds it manages.

How many Twist Bioscience (TWST) shares does EdgePoint have sole voting power over?

EdgePoint has sole voting power over 1,945,483 Twist Bioscience shares. It also shares voting power over an additional 576,152 shares through funds and trusts for which it acts as investment manager.

What is the total share count EdgePoint controls in Twist Bioscience (TWST)?

EdgePoint reports beneficial ownership of 2,521,635 Twist Bioscience shares. Of these, 1,945,483 are under sole voting and dispositive power and 576,152 under shared voting and dispositive power.

What does ‘5 percent or less of a class’ mean for Twist Bioscience (TWST)?

The Schedule 13G/A states EdgePoint’s holdings represent 5 percent or less of Twist Bioscience’s common stock. This reflects ownership below the 5% threshold that often triggers more extensive reporting requirements.

Who signed the Twist Bioscience (TWST) Schedule 13G/A for EdgePoint?

The amendment was signed by Sayuri Childs, Chief Compliance Officer of EdgePoint Investment Group Inc., dated 08/14/2026, certifying the accuracy of the reported beneficial ownership information.

What role does EdgePoint play regarding Twist Bioscience (TWST) shares?

EdgePoint acts as investment manager and exercises investment discretion over Twist Bioscience shares directly owned by various private investment funds and mutual fund trusts, rather than holding all shares directly itself.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/14/2026 - 08:42 AM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Twist Bioscience Corp

(Name of Issuer)

Common stock, $0.00001 par value per share

(Title of Class of Securities)

90184D100

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 90184D100

1

Names of Reporting Persons

EdgePoint Investment Group Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

ONTARIO, CANADA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,945,483.00
6	Shared Voting Power 576,152.00
7	Sole Dispositive Power 1,945,483.00
8	Shared Dispositive Power 576,152.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,521,635.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.21 %

12

Type of Reporting Person (See Instructions)

IA, FI

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Twist Bioscience Corp
(b)	Address of issuer's principal executive offices: 681 Gateway Blvd, South San Francisco, CA 94080
Item 2.
(a)	Name of person filing: This Schedule 13G is being filed on behalf of EdgePoint Investment Group Inc. ("EdgePoint") with respect to the Common Stock, with $0.00001 par value per share ("Common Stock"), of Twist Bioscience Corp (the "Issuer"). EdgePoint acts as investment manager to, and exercises investment discretion with respect to the Common Stock directly owned by, a number of private investment funds and mutual fund trusts.
(b)	Address or principal business office or, if none, residence: 150 Bloor Street West, Suite 700, Toronto, Ontario M5S 2X9, Canada
(c)	Citizenship: Ontario, Canada
(d)	Title of class of securities: Common stock, $0.00001 par value per share
(e)	CUSIP No.: 90184D100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
	NA
Item 4.	Ownership
(a)	Amount beneficially owned: 2,521,635
(b)	Percent of class: 4.21%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 1,945,483
	(ii) Shared power to vote or to direct the vote: 576,152
	(iii) Sole power to dispose or to direct the disposition of: 1,945,483
	(iv) Shared power to dispose or to direct the disposition of: 576,152
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

EdgePoint Investment Group Inc.

Signature:	Sayuri Childs
Name/Title:	Sayuri Childs | Chief Compliance Officer
Date:	08/14/2026